Broker Ratings

Merck & Co., Inc. – Consensus ‘buy’ rating and 14.0% Upside Potential

Merck & Co., Inc. which can be found using ticker (MRK) now have 25 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $155.00 and $124.50 with the average target price sitting at $143.00. Given that the stocks previous close was at $125.44 and the analysts are correct then we can expect a percentage increase in value of 14.0%. The day 50 moving average is $128.91 and the 200 moving average now moves to $119.00. The company has a market capitalization of 318.86B. The stock price for Affirm Holdings, Inc. is $125.89 USD

The potential market cap would be $363,491,142,008 based on the market consensus.

The company has a dividend yield of 2.05%. Other points of data to note are a P/E ratio of 141.45, revenue per share of $24.22 and a 10.26% return on assets.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services for the prevention, treatment and control of disease in all major livestock and companion animal species.

Share on:
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Merck & Co., Inc. (MRK) Investor Outlook: Analyzing a 18.35% Potential Upside with Strong Dividend Yields

    Merck & Co., Inc. (NYSE: MRK), a stalwart in the healthcare sector, continues to capture investor attention with its robust pharmaceutical portfolio and promising growth prospects. Headquartered in Rahway, New

    Merck & Company, Inc. (MRK) Stock Analysis: Evaluating a 16.40% Potential Upside for Investors

    Merck & Company, Inc. (NYSE: MRK), a stalwart in the healthcare sector, commands a market cap of $218.53 billion and holds a prominent position in the drug manufacturing industry. With

    Merck & Company, Inc. (MRK) Stock Analysis: Exploring a 20% Potential Upside for Investors

    As a cornerstone of the healthcare sector, Merck & Company, Inc. (NYSE: MRK) stands out in the pharmaceutical industry with a robust array of products and a rich history dating

    Merck & Company, Inc. (MRK) Stock Analysis: Navigating a 17.92% Potential Upside in the Healthcare Sector

    Merck & Company, Inc. (NYSE: MRK) stands as a towering presence in the healthcare sector, particularly within the drug manufacturing industry. With a substantial market capitalization of $214.78 billion, this

    Merck & Company, Inc. (MRK) Stock Analysis: Evaluating a 13.92% Potential Upside in the Healthcare Sector

    As one of the stalwarts in the healthcare industry, Merck & Company, Inc. (NYSE: MRK) remains an attractive proposition for investors with its robust pharmaceutical portfolio and potential upside. With

    Merck & Company, Inc. (MRK) Stock Analysis: A 29% Upside Potential Amid Strong Dividends

    Merck & Company, Inc. (NYSE: MRK), a stalwart in the healthcare sector, is capturing investor attention with its combination of robust dividends and a notable upside potential. With a market

      Search

      Search